News >

KTE-X19 Pivotal MCL Data Published in NEJM as FDA Weighs Approval

Jason M. Broderick @jasoncology
Published: Saturday, Apr 04, 2020

Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center

Michael Wang, MD

Findings from the pivotal phase II ZUMA-2 trial of KTE-X19 as a treatment for adult patients with relapsed/refractory mantle cell lymphoma (MCL) were published in the New England Journal of Medicine, as the FDA considers a biologics license application (BLA) for the CAR T-cell therapy for an approval in this setting.1,2
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication